Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome: A Multicenter Study–Part 2

BACKGROUND—Implantable cardioverter-defibrillator indications in Brugada syndrome remain controversial, especially in asymptomatic patients. Previous outcome data are limited by relatively small numbers of patients or short follow-up durations. We report the outcome of patients with Brugada syndrome...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2013-10, Vol.128 (16), p.1739-1747
Hauptverfasser: Sacher, Frédéric, Probst, Vincent, Maury, Philippe, Babuty, Dominique, Mansourati, Jacques, Komatsu, Yuki, Marquie, Christelle, Rosa, Antonio, Diallo, Abou, Cassagneau, Romain, Loizeau, Claire, Martins, Raphael, Field, Michael E, Derval, Nicolas, Miyazaki, Shinsuke, Denis, Arnaud, Nogami, Akihiko, Ritter, Philippe, Gourraud, Jean-Baptiste, Ploux, Sylvain, Rollin, Anne, Zemmoura, Adlane, Lamaison, Dominique, Bordachar, Pierre, Pierre, Bertrand, Jaïs, Pierre, Pasquié, Jean-Luc, Hocini, Mélèze, Legal, François, Defaye, Pascal, Boveda, Serge, Iesaka, Yoshito, Mabo, Philippe, Haïssaguerre, Michel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND—Implantable cardioverter-defibrillator indications in Brugada syndrome remain controversial, especially in asymptomatic patients. Previous outcome data are limited by relatively small numbers of patients or short follow-up durations. We report the outcome of patients with Brugada syndrome implanted with an implantable cardioverter-defibrillator in a large multicenter registry. METHODS AND RESULTS—A total of 378 patients (310 male; age, 46±13 years) with a type 1 Brugada ECG pattern implanted with an implantable cardioverter-defibrillator (31 for aborted sudden cardiac arrest, 181 for syncope, and 166 asymptomatic) were included. Fifteen patients (4%) were lost to follow-up. During a mean follow-up of 77±42 months, 7 patients (2%) died (1 as a result of an inappropriate shock), and 46 patients (12%) had appropriate device therapy (5±5 shocks per patient). Appropriate device therapy rates at 10 years were 48% for patients whose implantable cardioverter-defibrillator indication was aborted sudden cardiac arrest, 19% for those whose indication was syncope, and 12% for the patients who were asymptomatic at implantation. At 10 years, rates of inappropriate shock and lead failure were 37% and 29%, respectively. Inappropriate shock occurred in 91 patients (24%; 4±4 shocks per patient) because of lead failure (n=38), supraventricular tachycardia (n=20), T-wave oversensing (n=14), or sinus tachycardia (n=12). Importantly, introduction of remote monitoring, programming a high single ventricular fibrillation zone (>210–220 bpm), and a long detection time were associated with a reduced risk of inappropriate shock. CONCLUSIONS—Appropriate therapies are more prevalent in symptomatic Brugada syndrome patients but are not insignificant in asymptomatic patients (1%/y). Optimal implantable cardioverter-defibrillator programming and follow-up dramatically reduce inappropriate shock. However, lead failure remains a major problem in this population.
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.113.001941